Dr Reddys Laboratories Stock Current Valuation
| RDDA Stock | 14.70 0.20 1.38% |
Valuation analysis of Dr Reddys Laboratories helps investors to measure Dr Reddys' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Dr Reddys' price fluctuation is very steady at this time. Calculation of the real value of Dr Reddys Laboratories is based on 3 months time horizon. Increasing Dr Reddys' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Dr Reddys' intrinsic value may or may not be the same as its current market price of 14.70, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.7 | Real 14.3 | Hype 14.7 | Naive 14.91 |
The intrinsic value of Dr Reddys' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Dr Reddys' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Dr Reddys Laboratories helps investors to forecast how RDDA stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dr Reddys more accurately as focusing exclusively on Dr Reddys' fundamentals will not take into account other important factors: Dr Reddys Laboratories Company Current Valuation Analysis
Dr Reddys' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Dr Reddys Current Valuation | 8.47 B |
Most of Dr Reddys' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Dr Reddys Laboratories has a Current Valuation of 8.47 B. This is much higher than that of the sector and significantly higher than that of the Current Valuation industry. The current valuation for all Germany stocks is notably lower than that of the firm.
RDDA Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Reddys' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics of similar companies.Dr Reddys is currently under evaluation in current valuation category among its peers.
RDDA Fundamentals
| Current Valuation | 8.47 B | |||
| Price To Book | 3.61 X | |||
| Price To Sales | 3.35 X | |||
| Revenue | 214.39 B | |||
| EBITDA | 45.08 B | |||
| Net Income | 23.57 B | |||
| Total Debt | 3.8 B | |||
| Cash Flow From Operations | 28.11 B | |||
| Price To Earnings To Growth | 1.50 X | |||
| Market Capitalization | 8.93 B | |||
| Total Asset | 292.83 B | |||
| Z Score | 1.2 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 292.83 B |
About Dr Reddys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RDDA Stock Analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.